CR20250509A - Compuestos anti-vih - Google Patents

Compuestos anti-vih

Info

Publication number
CR20250509A
CR20250509A CR20250509A CR20250509A CR20250509A CR 20250509 A CR20250509 A CR 20250509A CR 20250509 A CR20250509 A CR 20250509A CR 20250509 A CR20250509 A CR 20250509A CR 20250509 A CR20250509 A CR 20250509A
Authority
CR
Costa Rica
Prior art keywords
hiv compounds
administering
treating
processes
formula
Prior art date
Application number
CR20250509A
Other languages
English (en)
Inventor
Doris T Tang
Bindu Goyal
Nathan D Shapiro
Michael O'neil Hanrahan Clarke
Raheel Fondekar
Gediminas J Brizgys
Bradley Thomas Reid
Luisruben P Martinez
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20250509A publication Critical patent/CR20250509A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención proporciona compuestos que tienen la Fórmula (I): o una sal farmacéuticamente aceptable de esta, así como composiciones farmacéuticas que comprenden las mismas, procesos para su preparación, y métodos para tratar y prevenir la infección por VIH mediante su administración.
CR20250509A 2023-05-31 2024-05-29 Compuestos anti-vih CR20250509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363470139P 2023-05-31 2023-05-31
PCT/US2024/031478 WO2024249517A1 (en) 2023-05-31 2024-05-29 Anti-hiv compounds

Publications (1)

Publication Number Publication Date
CR20250509A true CR20250509A (es) 2026-01-12

Family

ID=91620645

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250509A CR20250509A (es) 2023-05-31 2024-05-29 Compuestos anti-vih

Country Status (15)

Country Link
US (1) US20250051375A1 (es)
EP (1) EP4719602A1 (es)
KR (1) KR20260018876A (es)
CN (1) CN121464144A (es)
AR (1) AR132842A1 (es)
AU (1) AU2024283382A1 (es)
CL (1) CL2025003690A1 (es)
CO (1) CO2025016290A2 (es)
CR (1) CR20250509A (es)
DO (1) DOP2025000295A (es)
IL (1) IL324431A (es)
MX (1) MX2025013861A (es)
PE (1) PE20260297A1 (es)
TW (1) TW202500128A (es)
WO (1) WO2024249517A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
EP2116532B1 (en) 2007-06-12 2011-12-07 Concert Pharmaceuticals, Inc. Azapeptide derivatives as HIV protease inhibitors
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
PE20151063A1 (es) 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物

Also Published As

Publication number Publication date
CO2025016290A2 (es) 2025-12-09
DOP2025000295A (es) 2025-12-30
EP4719602A1 (en) 2026-04-08
IL324431A (en) 2026-01-01
TW202500128A (zh) 2025-01-01
US20250051375A1 (en) 2025-02-13
PE20260297A1 (es) 2026-02-10
MX2025013861A (es) 2026-01-07
CL2025003690A1 (es) 2026-03-13
CN121464144A (zh) 2026-02-03
WO2024249517A1 (en) 2024-12-05
AR132842A1 (es) 2025-08-06
KR20260018876A (ko) 2026-02-09
AU2024283382A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
ZA202500439B (en) Therapeutic compounds for hiv virus infection
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
AR119174A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
CO2022011947A2 (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
ECSP109897A (es) Composiciones terapeuticas y usos de las mismas
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
DOP2025000295A (es) Compuestos anti-vih
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MD4898B1 (ro) Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
BR112022017832A2 (pt) Inibidores de replicação do vírus da imunodeficiência humana
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
MX2022012321A (es) Composiciones viricidas y uso de las mismas.
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
BR112022010204A2 (pt) Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo